plerixafor has been researched along with su 11248 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Baracos, VE; Bathe, OF; Cervo, L; Giavazzi, R; Lecker, SH; Martinelli, GB; Olivari, D; Ottoboni, L; Piccirillo, R; Re Cecconi, AD; Resovi, A; Stretch, C; Talamini, L | 1 |
1 review(s) available for plerixafor and su 11248
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for plerixafor and su 11248
| Article | Year |
|---|---|
Activation of the SDF1/CXCR4 pathway retards muscle atrophy during cancer cachexia.
Topics: Animals; Benzylamines; Biomarkers; Cachexia; Chemokine CXCL12; Cyclams; Cytokines; Disease Models, Animal; Female; Gene Expression; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds; Humans; Indoles; Male; Mice; Muscle Fibers, Skeletal; Muscle, Skeletal; Muscular Atrophy; Neoplasms; Pyrroles; Rats; Receptors, CXCR4; Signal Transduction; Sunitinib | 2016 |